Indian pharmaceutical giant Cipla is gearing up for a major leadership change, with Umang Vohra, the company's Managing Director and Global CEO, reportedly planning to step down by the end of the current fiscal year. Vohra, 54, has led Cipla for nearly a decade and played a pivotal role in steering the company through key industry shifts and global healthcare challenges.

According to a report by Mint, Achin Gupta, Cipla’s current Global Chief Operating Officer, is likely to succeed Vohra. An industry executive familiar with the matter revealed that Gupta has been carefully groomed for the top role over the past few years. He initially joined to lead the India business and is expected to officially assume CEO responsibilities by March 2026.

Cipla is one of India’s largest and most influential pharmaceutical firms, known globally for its wide-ranging portfolio. The company produces active pharmaceutical ingredients (APIs) and a variety of pharmaceutical and personal care products, including widely used medications like escitalopram oxalate, lamivudine, and fluticasone propionate. It also holds the distinction of being the world’s largest manufacturer of antiretroviral drugs.

During the COVID-19 pandemic, Cipla played a critical role in India’s emergency response. In July 2020, the company launched Remdesivir under the brand name CIPREMI, after entering into a voluntary licensing agreement with Gilead Sciences and securing approval from India’s Drug Controller General (DCGI). The drug was authorized for “restricted emergency use” in treating critically ill COVID-19 patients.

This leadership change, if confirmed, would mark a significant shift in Cipla's strategic direction, potentially ushering in a new era of operational focus and market expansion under Gupta’s stewardship.

Cipla manufactures active pharmaceutical ingredients for other companies, as well as pharmaceutical and personal care products, including escitalopram oxalate, lamivudine, and fluticasone propionate.

The company is the world’s largest producer of antiretroviral drugs. In July 2020, Cipla launched Remdesivir under the brand name CIPREMI in India for “restricted emergency use” in critically ill COVID-19 patients, following a voluntary licensing agreement with Gilead Sciences and approval from the DCGI.